We’ve gone through blood, sweat, and tears to get here. This validates everything we’ve built,' Saldanha said.

AbbVie Inc. (NYSE:ABBV) saw its stock jump 3.4% after announcing a major licensing agreement with IGI Therapeutics, securing ...

IGI Therapeutics SA, a wholly-owned subsidiary of Ichnos Glenmark Innovation (IGI)—an alliance between Glenmark Pharma and Ichnos Sciences Inc.—has signed an exclusive licensing agreement with AbbVie ...

The U.S. market stands out with a projected USD 377.1 billion valuation by 2034, thanks to robust R&D and government support, enhancing treatment accessibility and precision oncology adoption. Dublin, ...

AbbVie presented a user case study on the collaboration at Emerson Exchange 2025, held May 19-22 in San Antonio, Texas, showing how the implementation of wireless, real-time steam trap monitoring ...

AbbVie, a global biopharmaceutical major, announced its entry into the Indian oncology market with the introduction of Venetoclax for the treatment of both acute myeloid leukaemia (AML) and chronic ...

AbbVie Inc . (NYSE: ABBV), a leading biopharmaceutical company with a market capitalization of $375 billion, has been navigating a complex landscape of challenges and opportunities as it transitions ...